Esperion delivered robust second quarter 2025 results, with total revenue increasing 12% year-over-year to $82.4 million, driven by a 42% surge in U.S. net product revenue. The company achieved its first quarter of operating income from ongoing business and expects sustainable profitability starting in Q1 2026. Key accomplishments include settlement agreements protecting intellectual property until 2040 and continued expansion of market access for its therapies.

Esperion reported a total revenue of $65.0 million for Q1 2025, a 53% decrease year-over-year, primarily due to a one-time milestone received in Q1 2024. Excluding this milestone, total revenue grew 63%. The company achieved a net loss of $40.5 million and a basic net loss per share of $0.21.

Esperion's Q4 2024 revenue increased 114% year-over-year to $69.1 million, driven by strong prescription growth. The company's net loss improved significantly to $21.3 million from $56.3 million in Q4 2023. The company continues to expand globally and develop new combination therapies.

Esperion reported a strong third quarter in 2024, marked by significant revenue growth and prescription increases. Total revenue increased by 52% year-over-year to $51.6 million, driven by a 53% increase in U.S. net product revenue. Key achievements included expanded product labels, a scaled-up commercial team, and successful new indication launches, contributing to double-digit prescription growth. The company also strengthened its balance sheet by monetizing European royalties and paying off a revenue interest facility.

Esperion reported a strong second quarter in 2024, highlighted by a 186% increase in total revenue to $73.8 million compared to the same period last year. The company also monetized its European royalties for $304.7 million and used the proceeds to pay off its Oberland revenue interest facility, enhancing financial flexibility. U.S. net product revenue grew by 39%, driven by increased retail prescription growth.

Esperion reported a remarkable 467% year-over-year increase in total revenue, reaching $137.7 million in Q1 2024. This growth was driven by a 46% increase in U.S. net product revenue and a significant rise in collaboration revenue. The company also achieved FDA approval for expanded labels for NEXLETOL and NEXLIZET, positioning it for further growth.

Esperion reported a 72% increase in Q4 total revenue, driven by U.S. net product revenue growth of 39% and collaboration revenue growth of 195%. The company also resolved litigation with DSE, securing $100 million and potential cost savings. They are preparing for potential cardiovascular risk reduction label approvals from the FDA and EMA.

Esperion reported a 79% increase in total revenue to $34.0 million for Q3 2023, driven by a 45% increase in U.S. net product revenue and a 174% increase in collaboration revenue. The company also made progress toward label expansion, with FDA acceptance of cardiovascular risk reduction indication submissions in the U.S. The company reported a net loss of $41.3 million, and is preparing for new labels and sales organization changes to maximize the potential of NEXLETOL and NEXLIZET.

Esperion reported a 37% increase in total revenue for Q2 2023, driven by a 49% increase in U.S. net product revenue. The company submitted applications for expanded indications in the U.S. and Europe and presented new data demonstrating significant cardiovascular risk reduction.

Esperion reported a 29% increase in total revenue to $24.3 million for Q1 2023, driven by a 27% increase in U.S. net product revenue and a 33% increase in collaboration revenue. The company highlighted the positive reception of the CLEAR Outcomes trial and strengthened its capital position with $56 million in financing. However, the company experienced a net loss of $61.7 million.

Esperion reported a Q4 2022 revenue of $18.8 million, driven by increased U.S. product and royalty revenue. The company also highlighted the successful completion of the CLEAR Outcomes trial and a 41% reduction in selling, general, and administrative expenses.

Esperion reported a total revenue of $19.0 million for Q3 2022, a 32% increase compared to the same period in 2021. U.S. product revenue grew by 28% year-over-year, reaching $14.0 million. The company's net loss for the quarter was $55.1 million, with a reduced SG&A expenses by 36% year-over-year.

Esperion reported Q2 2022 financial results, with total revenue of $18.8 million, a decrease of 54% compared to Q2 2021. U.S. product revenue grew 28% year-over-year to $13.6 million. The CLEAR Outcomes trial reached 100% MACE accumulation, and topline results are expected in Q1 2023.

Esperion reported a strong first quarter with a 135% increase in total revenue compared to the previous year, driven by growth in U.S. product revenue and royalties. The company is advancing its CLEAR Outcomes trial and reaffirming its financial outlook for 2022.

Esperion reported a U.S. net product revenue of $12.2 million for Q4 2021, a 12% sequential increase. The company also achieved 90% MACE accumulation in the CLEAR Outcomes trial and secured $209 million in financing, extending its cash runway beyond the CLEAR Outcomes top-line results.

Esperion reported U.S. net product revenue of $10.9 million for Q3 2021. The company is focusing on aligning its operational and expense structure for long-term growth, with the CLEAR Outcomes study on track for MACE accumulation in 2H 2022.

Esperion reported a net loss of $43.7 million for Q2 2021, with total revenues of $40.7 million. U.S. net product revenue grew 67% sequentially to $10.6 million, driven by increased demand and improved net price. The company is progressing with its CLEAR Outcomes study and expects complete MACE accumulation in 2H 2022.

Esperion reported total revenue of $8.0 million for the first quarter of 2021, compared to $1.8 million for the first quarter of 2020. U.S. product revenue was $6.4 million, an increase from $0.9 million in the prior year. The company experienced a net loss of $90.9 million, or $3.50 per share, compared to a net loss of $78.2 million, or $2.84 per share, for the same period in 2020.

Esperion reported a total revenue of $9.6 million for Q4 2020, driven by U.S. product revenue of $8.2 million. The company's net loss was $104.5 million. They made progress on the CLEAR Outcomes trial and strengthened their balance sheet.

Esperion's Q3 2020 total revenue was $3.8 million, including $3.3 million from net product sales and $0.5 million from partner reimbursement. The company's net loss was $85.4 million, or $3.07 per share.

Esperion reported a strong Q2 2020, marked by record quarterly and first-half revenue, driven by collaboration revenue and initial product sales of NEXLETOL and NEXLIZET. The company successfully navigated the COVID-19 pandemic, strengthened its balance sheet, and secured broad managed care coverage for its new medicines.

Esperion reported first quarter results with $1.8 million in total revenue, including $0.8 million from NEXLETOL sales and $1.0 million from collaboration revenue. The company had a net loss of $78.2 million, or $2.84 per share. They ended the quarter with $158.2 million in cash and expect an additional $150 million from Daiichi Sankyo Europe upon first commercial sale in the EU.